Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 4/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 3/20 | 0.36 |
| ▸ | MMP9 | P14780 | 2/20 | 0.36 |
| ▸ | MMP14 | P50281 | 2/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12018425 | 1.00 | MMP2 (0.44) | MMP2CA12CA1CA2CA9 | |
| SCHEMBL12402476 | 0.98 | MMP2 (0.41) | MMP2CA12CA1CA2CA9 | |
| SCHEMBL12295863 | 0.95 | MMP2 (0.38) | MMP2CA12CA1CA2CA9 | |
| SCHEMBL3269754 | 0.95 | MMP2 (0.38) | MMP2CA12CA1CA2CA9 | |
| SCHEMBL3265363 | 0.91 | SMN1; SMN2 (0.33) | MMP2CA12CA1CA2CA9 | |
| SCHEMBL8911457 | 0.91 | SMN1; SMN2 (0.33) | MMP2CA12CA1CA2CA9 | |
| SCHEMBL8912843 | 0.91 | SMN1; SMN2 (0.33) | MMP2CA12CA1CA2CA9 | |
| SCHEMBL10045005 | 0.88 | MMP2 (0.39) | MMP2CA12CA1CA2CA9 | |
| SCHEMBL10044936 | 0.84 | AAK1 (0.45) | MMP2CA12CA1CA2CA9 | |
| SCHEMBL10045004 | 0.84 | ALDH1A1 (0.41) | MMP2CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940688-B2 | Fluorinated tripeptide HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8940688-B2 | Fluorinated tripeptide HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8785377-B2 | Tetrazolyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785377-B2 | Tetrazolyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8501682-B2 | Difluorinated tripeptides as HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501682-B2 | Difluorinated tripeptides as HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8361958-B2 | Oximyl HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8361958-B2 | Oximyl HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8263549-B2 | C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-8101567-B2 | Heteroaryl-containing tripeptide HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20090155210-A1 | OXIMYL HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-06-18 | — | — | US | disclosed |
| WO-2009070689-A1 | BICYCLIC, C5-SUBSTITUTED PROLINE DERIVATIVES AS INHIBITORS OF THE HEPATITIS C VIRUS NS3 PROTEASE | ENANTA PHARMACEUTICALS, INC. (US) | 2009-06-04 | — | — | WO | disclosed |
| WO-2009070692-A1 | C5-SUBSTITUTED, PROLINE-DERIVED, MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2009-06-04 | — | — | WO | disclosed |
| US-20090130059-A1 | TETRAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-05-21 | — | — | US | disclosed |
| US-20090035271-A1 | TETRAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-02-05 | — | — | US | disclosed |
| US-20090035271-A1 | TETRAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-02-05 | — | — | US | disclosed |
| US-20080187516-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080187516-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080125444-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-05-29 | — | — | US | disclosed |
| US-20080125444-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090035271-A1 | TETRAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | TMPRSS4, PRSS1, SPINT2 | MMP2 145/4885CA12 1939/4885CA1 1572/4885 |
| US-20080125444-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | CPN1, HPN, HCCS | MMP2 153/4885CA12 694/4885CA1 799/4885 |
| US-20090155210-A1 | OXIMYL HCV SERINE PROTEASE INHIBITORS | PRSS1, HPN, SPINT2 | MMP2 195/4885CA12 1041/4885CA1 1563/4885 |
| US-20090130059-A1 | TETRAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | TMPRSS4, PRSS1, SPINT2 | MMP2 145/4885CA12 1939/4885CA1 1572/4885 |
| US-20080187516-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | CPN1, HPN, HCCS | MMP2 153/4885CA12 694/4885CA1 799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.